Quick Answer
Rani Therapeutics Holdings, Inc. reported Cash and Equivalents of $18.62 million for fiscal year 2025.
Rani Therapeutics Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $18.62M | +394.9% |
| 2024 | $3.76M | -35.8% |
| 2023 | $5.86M | -78.3% |
| 2022 | $27.01M | -77.0% |
| 2021 | $117.45M | +60.8% |
| 2020 | $73.06M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.14M | -3.1% | -59.4% |
| June 30, 2025 | $10.22M | +126.3% | +1.0% |
| March 31, 2025 | $10.11M | +47.0% | +168.8% |
| December 31, 2024 | $3.76M | -35.8% | -12.0% |
| September 30, 2024 | $4.28M | -14.0% | -5.3% |
| June 30, 2024 | $4.51M | -40.2% | -34.4% |
| March 31, 2024 | $6.88M | -63.8% | +17.3% |
| December 31, 2023 | $5.86M | -78.3% | +17.9% |
- Rani Therapeutics Holdings, Inc. showed an increase of +394.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Rani Therapeutics Holdings, Inc.’s cash and equivalents has declined by 74.5% (from $73.06 million to $18.62 million).
- The most recent figure is from Rani Therapeutics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: